Kolexia
Giroux-Leprieur Etienne Pneumologie
Giroux-Leprieur Etienne
Pneumologie
Hôpital Ambroise Paré
Boulogne-Billancourt, France
203 Activités
491 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinomes Adénocarcinome COVID-19 Adénocarcinome pulmonaire Carcinome épidermoïde Métastase tumorale

Collaborateurs

Voir plus
Wislez Marie
Wislez Marie
Hôpital Cochin, Paris, France
Cadranel Jacques
Cadranel Jacques
Hôpital Tenon, Paris, France
Gounant Valerie
Gounant Valerie
Hôpital Bichat-Claude-Bernard, Paris, France
Emile Jean-Francois
Emile Jean-Francois
Hôpital Ambroise Paré, Boulogne-Billancourt, France

Industries

Voir plus
AstraZeneca
14 collaboration(s)
Dernière en 2022
Janssen
10 collaboration(s)
Dernière en 2023
Sanofi
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
ENCO-BRAF: A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
ROSIE: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
REBIMMUNE: Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Essai Clinique (Assistance publique – Hôpitaux de Paris)   12 février 2024
Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021.
ESMO open   09 février 2024
PACT-01: Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
Essai Clinique (Institut Curie)   29 janvier 2024
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Essai Clinique (OncoC4, Inc.)   17 janvier 2024
Osimertinib chez les patients atteint d’un cancer bronchique non à petites cellules (CBNPC) muté EGFR présentant des métastases cérébrales ou leptoméningées: résultats de l’étude IFCT-1804 ORBITAL
28e Congrès de Pneumologie de Langue Française   01 janvier 2024
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands)   24 décembre 2023
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Essai Clinique (Razor Genomics)   20 décembre 2023